Business Wire

  1. AI Drug Discovery Leaders Gain A Competitive Edge With Telesis Bio's Gibson SOLA Platform, Generating Development Candidates Faster 8/25/2026

    Telesis Bio Inc., maker of the world’s only intelligent, on-premises DNA synthesis solution for AI labs, today announced recent commercial licensing agreements with several AI-native drug discovery companies.

  2. Chai Discovery Announces Collaboration With Bristol Myers Squibb To Advance AI-Driven Antibody Discovery 8/20/2026

    Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with Bristol Myers Squibb to advance the discovery of therapeutic antibodies using artificial intelligence.

  3. GenBio AI Builds First World Model Of The Human Cell 8/18/2026

    GenBio AI ('GenBio') is an AI for Science company co-founded by Nobel Laureate David Baker, leading AI scientist Eric Xing, and other prominent life science and artificial intelligence researchers from Stanford, Carnegie Mellon University, Mohamed Bin Zayed University of Artificial Intelligence, Harvard, Weizmann Institute, and other research institutions.

  4. Bruker Announces Majority Investment In MIMETAS To Advance Human Physiology-Relevant Drug Discovery And Development 8/10/2026

    Bruker Corporation today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development.

  5. Ono Pharma Enters Into A Drug Discovery Partnership With Mediar Therapeutics To Create Novel Antibody Therapeutics For Fibro-Inflammatory Diseases 8/6/2026

    Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) announced today that it has entered into a drug discovery partnership and option agreement with Mediar Therapeutics, Inc.

  6. Greenstone Biosciences Receives NIH R61 Grant To Advance Cardiac Fibrosis Therapeutics For Duchenne Muscular Dystrophy 8/6/2026

    Greenstone Biosciences, a biotechnology company advancing New Approach Methodologies (NAMs) for drug discovery, today announced that it has received a Catalyze R61 award from the National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH).

  7. Schrödinger Announces Strategic Collaboration And Software Agreement With Bristol Myers Squibb To Deploy AI Co-Scientist Bunsen For Agentic Drug Discovery 8/5/2026

    Schrödinger, Inc. today announced a strategic agreement with Bristol Myers Squibb (BMS) to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization.

  8. IQVIA And Medera To Advance Cardiac Gene Therapy And Human-Based Drug Discovery 8/4/2026

    IQVIA, a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company pioneering next-generation therapeutics for cardiovascular disease, today announced a strategic collaboration to accelerate the development of cardiac gene therapies and human-based drug discovery platforms.

  9. U.S. FDA Grants Orphan Drug Designation To Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (NECs) 8/3/2026

    Zai Lab Limited today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company’s potential first-in-class Delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), for the treatment of neuroendocrine carcinomas (NECs).

  10. Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI As A Separate Company To Commercialize And Expand Its Multi-Agent AI Co-Scientist Platform For The Transformation Of Medicine 8/3/2026

    Lantern Pharma Inc. a clinical-stage AI-driven precision oncology company, today announced the formal creation of Open-Medicine AI (OMAI) and the execution of commercial licensing agreements between OMAI and Lantern Pharma.